ANI Pharmaceuticals, Inc. Q1 FY2026 earnings call

Nikhil Lalwani highlighted the acceleration of the transformation into a leading rare disease company. Cortofan gel net revenues grew 42% year over year, with strong momentum in new patient starts and monthly volumes. The rare disease organization is expanding to target acute gouty arthritis flares, with the commercial team expected to be fully deployed by end-June. Elluvian showed 20% year-over-year revenue growth with ongoing clinical data generation. The generic business launched six new products and maintained position as number two in CGT approvals. Capital allocation strategy includes inorganic opportunities and organic growth investments, with a new $100 million share repurchase program authorized.

Cortofan gel had net revenues of $75.1 million in the first quarter, up 42% year over year. Elluvian generated $19.3 million in revenue, up 20% year over year. An upfront license fee of $15 million was recognized from the Harmony Biosciences transaction. Generics revenue was $105.4 million in the first quarter, an increase of 7% year over year. Cortofan gel is expected to account for approximately 60% of total revenues in 2026, with growth driven by core indications and expansion into acute gouty arthritis flares.

ANI raised 2026 financial guidance. Total net revenue is expected to be in the range of $1.08 billion to $1.14 billion. Adjusted EBITDA is projected to be $285 million to $300 million. Cortofan gel net revenue guidance is reaffirmed at $540 million to $575 million. Elluvian net revenue is guided at $78 million to $83 million. Gross margin expectations are adjusted upward to 59.9% to 60.9%.

Seasonality related to insurance re-verifications impacted first quarter results. Market competition in rare disease and generics could affect performance. Regulatory changes may impact product launches and approvals.

Q: On the mix for Cortofan, how much growth is from non-gout settings and vial/duration dynamics?

A: Majority growth from core indications like rheumatology, nephrology, etc. Vials and duration vary by indication.

Q: Regarding Harmony deal, is the $10 million milestone included in guidance?

A: The milestone achievement clarity contributes to revised guidance.

Q: On Q2 SOC guidance for Cortofan and gout revenue expansion?

A: Momentum sustained with expansion into acute gouty arthritis flares team deployment.